Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

Jeffrey A. Switzer, David C. Hess, Adviye Ergul, Jennifer L. Waller, Livia S. MacHado, Vera Portik-Dobos, L. Creed Pettigrew, Wayne M. Clark, Susan C. Fagan

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.

Original languageEnglish (US)
Pages (from-to)2633-2635
Number of pages3
JournalStroke
Volume42
Issue number9
DOIs
StatePublished - Sep 1 2011

Fingerprint

Minocycline
Matrix Metalloproteinase 9
Stroke
Plasminogen Activators
Thrombolytic Therapy
Hemorrhage

Keywords

  • acute stroke
  • inflammation
  • neuroprotection

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. / Switzer, Jeffrey A.; Hess, David C.; Ergul, Adviye; Waller, Jennifer L.; MacHado, Livia S.; Portik-Dobos, Vera; Pettigrew, L. Creed; Clark, Wayne M.; Fagan, Susan C.

In: Stroke, Vol. 42, No. 9, 01.09.2011, p. 2633-2635.

Research output: Contribution to journalArticle

Switzer, Jeffrey A. ; Hess, David C. ; Ergul, Adviye ; Waller, Jennifer L. ; MacHado, Livia S. ; Portik-Dobos, Vera ; Pettigrew, L. Creed ; Clark, Wayne M. ; Fagan, Susan C. / Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. In: Stroke. 2011 ; Vol. 42, No. 9. pp. 2633-2635.
@article{1e920e1a732e4c3389ffa17aeff95d58,
title = "Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke",
abstract = "Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.",
keywords = "acute stroke, inflammation, neuroprotection",
author = "Switzer, {Jeffrey A.} and Hess, {David C.} and Adviye Ergul and Waller, {Jennifer L.} and MacHado, {Livia S.} and Vera Portik-Dobos and Pettigrew, {L. Creed} and Clark, {Wayne M.} and Fagan, {Susan C.}",
year = "2011",
month = "9",
day = "1",
doi = "10.1161/STROKEAHA.111.618215",
language = "English (US)",
volume = "42",
pages = "2633--2635",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

AU - Switzer, Jeffrey A.

AU - Hess, David C.

AU - Ergul, Adviye

AU - Waller, Jennifer L.

AU - MacHado, Livia S.

AU - Portik-Dobos, Vera

AU - Pettigrew, L. Creed

AU - Clark, Wayne M.

AU - Fagan, Susan C.

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.

AB - Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P<0.0001; non-tPA, P=0.0019). Conclusions-Lower plasma matrix metalloproteinase-9 was seen among tPA-treated subjects in the MINOS trial. Combining minocycline with tPA may prevent the adverse consequences of thrombolytic therapy through suppression of matrix metalloproteinase-9 activity.

KW - acute stroke

KW - inflammation

KW - neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=80052415005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052415005&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.111.618215

DO - 10.1161/STROKEAHA.111.618215

M3 - Article

C2 - 21737808

AN - SCOPUS:80052415005

VL - 42

SP - 2633

EP - 2635

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 9

ER -